Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus TT-628
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus TT-628 is a specific probiotic strain investigated for its potential therapeutic effects in neurological disorders, specifically epilepsy. As part of a microbial therapy approach, it is studied as an adjunctive treatment to standard antiepileptic drugs to help manage uncontrolled seizures. The strain is believed to exert its effects through the gut-brain axis, potentially modulating neuroinflammation, neurotransmitter levels (such as GABA), and the intestinal microbiome composition. Clinical research, primarily led by West China Hospital of Sichuan University, evaluates its safety and efficacy when administered orally, often in combination with other probiotic strains like Bacteroides fragilis BF839.
- Other names
- Lactobacillus rhamnosus TT-628L. rhamnosus TT-628
Beyond the preview
Go deeper on lactobacillus rhamnosus TT-628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus TT-628.